Dyslipidemia Market is Anticipated to Accelerate in the Coming 10 Years Due to the Development of New Classes of Drugs, Such as CETP Inhibitors and Gene-based Therapies | DelveInsight

The dyslipidemia market is expected to witness significant growth, driven by an aging population, increasing awareness of cardiovascular health, and the introduction of novel therapies such as AZD0780, Obicetrapib, Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and others. The anticipated…